Venrock Adviser, LLC
Top Portfolio Positions
33 positions ·
$2,679,121,844 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| APGE |
Apogee Therapeutics, Inc.
Healthcare
|
8,493,321 | $714,882,828 | 26.68% | |
| ERAS |
Erasca, Inc.
Healthcare
|
16,382,812 | $265,073,898 | 9.89% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
4,148,428 | $203,480,393 | 7.60% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
3,685,448 | $185,893,997 | 6.94% | |
| KALV |
KalVista Pharmaceuticals, Inc.
Healthcare
|
6,474,485 | $130,331,383 | 4.86% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
1,180,000 | $99,025,600 | 3.70% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
3,603,595 | $93,333,110 | 3.48% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
10,346,926 | $87,638,463 | 3.27% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
2,000,000 | $76,980,000 | 2.87% | |
| VRDN |
Viridian Therapeutics, Inc.DE
Healthcare
|
3,882,709 | $75,945,788 | 2.83% |
Portfolio Trend
25 quarters · across all stocks
Holdings in ENGN
Shares Held
Position Value (USD)
9 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $32,493,329 | 4,771,414 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $43,085,868 | 4,771,414 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $34,467,007 | 5,046,414 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $18,368,946 | 5,046,414 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $22,607,934 | 5,046,414 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $33,558,653 | 5,046,414 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $23,534,550 | 3,565,841 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $26,649,019 | 2,825,983 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $43,491,004 | 2,565,841 | Shares | Sole | 2024-05-15 | |
| No 13F history on record for this holder in this stock. | ||||||